PECS I Block for Breast Subpectoral Implant Surgery

University Hospital, Lille

Status

Completed

Conditions

Pain, Postoperative

Treatments

Drug: Ropivacaine (PECS bloc)

Drug: Placebo

Study type

Interventional

Funder types

Other

Identifiers

NCT02849236

2016-000157-12 (EudraCT Number)

2015_17

Details and patient eligibility

About

Breast augmentation surgery can cause important postoperative pain, especially when bilateral subpectoral implants are used. The investigators hypothesized that a technique of regional analgesia, the pectoral nerve block type I (or "PECS I block") would reduce pain within the first twenty-four hours and, in turn, morphine consumption and associated side effects. This is a randomized, controlled, double-blind study which compares intra and postoperative analgesia with or without PECS I block in breast surgery.

Enrollment

56 patients

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Every female who will benefit of a bilateral subpectoral breast augmentation
Age more than 18 years
Social insured

Exclusion criteria

refusal of the patient
Age less than 18 years
Inability to consent
History of thoracic surgery or breast implants
Pregnancy
Inability to use a patient controlled analgesia
Contraindication of the use of opioids or local anesthetics
Pathology of hemostasis, infection
Can not use a PCA
Patients under long-term opioids (WHO pain ladder 2 and 3)
Patient presenting neuropathic pain during the preoperative period (score greater than or equal to 4 to the DN4 questionnaire, or taking anti-epileptic or antidepressant treatments for neuropathic pain)